For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development | 1,854 | |||
| Selling, general and administrative | 3,780 | |||
| Total operating expenses | 5,634 | |||
| Loss from operations | -5,634 | |||
| Change in fair value of derivative liability | 33 | |||
| Interest income | 24 | |||
| Interest expense | 648 | |||
| Net other (expense) income | -591 | |||
| Net loss from operations before discontinued operations | -6,225 | |||
| Revenue | 24 | |||
| Cost of sales | 3 | |||
| Gross profit | 21 | |||
| Selling, general and administrative | -2 | |||
| Total operating expenses | -2 | |||
| Income (loss) from discontinued operations | 23 | |||
| Net loss | -6,202 | |||
| Basic EPS | -2.23 | |||
| Basic Average Shares | 2,883,650 | |||
Valion Bio, Inc. (VBIO)
Valion Bio, Inc. (VBIO)